NEW_VeronaCorp_Logo_Inline_With_RGB - for notfied.jpg
Andrew Fisher Joins Verona Pharma as General Counsel
March 04, 2024 02:00 ET | Verona Pharma plc
Verona Pharma announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team.
NEW_VeronaCorp_Logo_Inline_With_RGB - for notfied.jpg
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 29, 2024 02:00 ET | Verona Pharma plc
PDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong balance sheet supports commercialization and Company's growth Conference call today at 9:00...
Verona logo.jpg
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
February 15, 2024 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth...
Verona logo.jpg
Michael Austwick Joins Verona Pharma as Non-Executive Director
February 01, 2024 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. ...
Verona logo.jpg
Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at...
Verona logo.jpg
Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital
January 02, 2024 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (the “Company”),...
Verona logo.jpg
Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award
November 17, 2023 02:00 ET | Verona Pharma plc
Verona Pharma plc announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023' at the SCRIP awards.
Verona logo.jpg
Verona Pharma Announces November 2023 Investor Conference Participation
November 08, 2023 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at...
Verona logo.jpg
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 02, 2023 03:04 ET | Verona Pharma plc
US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference...
Verona logo.jpg
Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update
October 19, 2023 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...